Skip to main content
SpringerLink
Log in

Side effects and drug interactions

  • Chapter
St. John’s Wort and its Active Principles in Depression and Anxiety

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Harrer G, Payk TR, Schulz V (Hrsg.) (1993) Hypericum als pflanzliches Antidepressivum. Nervenheilkunde 12: 268–366

    Google Scholar 

  2. Jenike MA (ed.) (1994) Hypericum: A noval antidepressant. J Geriatr Psychiatry Neurol 7(Suppl 1): 1–68

    Google Scholar 

  3. Müller WE, Kasper S (eds) (1997) Hypericum extract (LI 160) as a herbal antidepressant. Pharmacopsychiatry 30(Suppl II): 71–134

    Google Scholar 

  4. Müller WE, Chatterjee SS (eds) (1998) Hyperforin and the antidepressant activity of St. John’s Wort. Pharmacopsychiatry 31(Suppl I): 1–60

    Google Scholar 

  5. Knüppel L, Linde K (2004) Adverse effects of St John’s Wort — An overview. J Clin Psychiatry 65: 1470–1479

    PubMed  Google Scholar 

  6. Volz HP, Zeller K (2000) Hochdosierter Johanniskrautextrakt als Einmalgabe. Ergebnisse einer Anwendungsbeobachtung an 11296 Patienten. Nervenheilkunde 19: 566–569

    Google Scholar 

  7. Woelk H, Burkhard G, Grünwald J (1994) Benefits and risks of the Hypericum extract LI 160: Drug monitoring study with 3250 patients. J Geriatr Psychiatry Neurol 7(Suppl 1): 34–38

    Google Scholar 

  8. Schulz V (2001) Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine 8: 152–160

    PubMed  Google Scholar 

  9. Araya OS, Ford EJH (1981) An investigation of the type of photosensitization caused by the ingestion of St. John’s Wort (Hypericum perforatum) by calves. J Comp Pathol 91: 135–141

    Article  PubMed  Google Scholar 

  10. Giese AC (1980) Hypericism. Photochem Photobiol Rev 39: 229–255

    Google Scholar 

  11. Fugh-Berman A, Ernst E (2001) Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 52: 587–595

    Article  PubMed  Google Scholar 

  12. Mannel M (2004) St. John’s Wort drug interactions — review of mechanisms and clinical implications. Drug Saf 27: 773–797

    PubMed  Google Scholar 

  13. Ladner DP, Klein SD, Steiner RA, Walt H (2001) Synergistic toxicity of delta-aminolaevulinic acid-induced protoporphyrin IX used for photodiagnosis and Hypericum extract, a herbal antidepressant. Br J Dermatol 144: 916–918

    Article  PubMed  Google Scholar 

  14. NN (1984) Monographie Hyperici herba (Johanniskraut). Bundesanzeiger Nr. 228, 05.12.1984

    Google Scholar 

  15. Brockmöller J, Reum T, Bauer S, Kerb R, Hübner WD, Roots I (1997) Hypericin and pseudohy-pericin: Pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 30(Suppl): 94–101

    PubMed  Google Scholar 

  16. Schempp CM, Winghofer B, Müller K, Schulte-Mönting J, Mannel M, Schöpf E, Simon J (2003) Effect of oral administration of Hypericum perforatum extract (St. John’s Wort) on skin erythema and pigmentation induced by UVB, UVA, visible light and solar simulated radiation. Phytotherapy Res 17: 141–146

    Article  Google Scholar 

  17. Bove GM (1998) Acute neuropathy after exposure to sun in a patient treated with St John’s Wort. Lancet 352: 1121–1122

    Article  Google Scholar 

  18. Golsch S, Vocks E, Rakoski J, Brockow K, Ring J (1997) Reversible Erhöhung der Photosensitivität im UV-B-Bereich durch Johanniskraut-Präparate. Der Hautarzt 48: 249–252

    Article  Google Scholar 

  19. Gulick RM, McAuliffe V, Holden-Wiltse J, Crumpacker C, Liebes L, Stein DS, Meehan P, Hussey S, Forcht J, Valentine FT (1999) Phase I studies of hypericin, the active compound in St. John’s Wort, as an antiretroviral agent in HIV-infected adults. Ann Intern Med 130: 510–514

    PubMed  Google Scholar 

  20. Holme SA, Roberts DL (2000) Erythroderma associated with St John’s Wort. Br J Dermatol 143: 1127–1128

    PubMed  Google Scholar 

  21. Lane-Brown MM (2000) Photosensitivity associated with herbal preparations of St John’s Wort (Hypericum perforatum). Med J Aust 172: 302

    Google Scholar 

  22. Gordon J (1998) SSRIs and St John’s Wort: possible toxicity? Am Fam Physician 62: 31

    Google Scholar 

  23. Lantz MS, Buchalter E, Giambanco V (1999) St John’s Wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 12: 7–10

    PubMed  Google Scholar 

  24. Demott K (1998) St. John’s Wort tied to serotonine syndrome. Clin Psychiatry News 26: 28

    Google Scholar 

  25. Walter G, Rey JM, Harding A (2000) Psychiatrists’ experience and views regarding St John’s Wort and ‘alternative’ treatments. Aust N Z J Psychiatry 34: 992–996

    PubMed  Google Scholar 

  26. Parker V, Wong AH, Boon HS, Seeman MV (2001) Adverse reactions to St John’s Wort. Can J Psychiatry 46: 77–79

    PubMed  Google Scholar 

  27. Greeson JM, Sanford B, Monti DA (2001) St. John’s Wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology 153: 402–414

    PubMed  Google Scholar 

  28. Müller WE (2003) Current St. John’s Wort research from mode of action to clinical efficacy. Pharmacol Res 47: 101–109

    Article  PubMed  Google Scholar 

  29. O’Breasail AM, Argouarch S (1998) Hypomania and St John’s Wort. Can J Psychiatry 43: 746–747

    PubMed  Google Scholar 

  30. Schneck C (1998) St. John’s Wort and hypomania. J Clin Psychiatry 59: 689

    Google Scholar 

  31. Nierenberg AA, Burt T, Matthews J, Weiss AP (1999) Mania associated with St. John’s Wort. Biol Psychiatry 46: 1707–1708

    PubMed  Google Scholar 

  32. Moses EL, Mallinger AG (2000) St. John’s Wort: three cases of possible mania induction. J Clin Psychopharmacol 20: 115–117

    PubMed  Google Scholar 

  33. Barbenel DM, Yusufi B, O’Shea D, Bench CJ (2000) Mania in a patient receiving testosterone replacement postorchidectomy taking St John’s Wort and sertraline. J Psychopharmacol 14: 84–86

    PubMed  Google Scholar 

  34. Spinella M, Eaton LA (2002) Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Inj 16: 359–367

    PubMed  Google Scholar 

  35. Gordon JB (1998) SSRIs and St. John’s Wort: possible toxicity? Am Fam Physician 57: 950

    PubMed  Google Scholar 

  36. Crowe S, McKeating K (2002) Delayed emergence and St. John’s Wort. Anesthesiology 96: 1025–1027

    PubMed  Google Scholar 

  37. Schmidt U, Harrer G, Kuhn U, Berger-Deinert W, Luther D (1993) Wechselwirkungen von Hypericum-Extrakt mit Alkohol. Nervenheilkunde 12: 314–319

    Google Scholar 

  38. Irefin S, Sprung J (2000) A possible cause of cardiovascular collapse during anesthesia: long-term use of St. John’s Wort. J Clin Anesth 12: 498–499

    Google Scholar 

  39. Zullino D, Borgeat F (2003) Hypertension induced by St. John’s Wort. Pharmacopsychiatry 36: 32

    PubMed  Google Scholar 

  40. Patel S, Robinson R, Burk M (2002) Hypertensive crisis associated with St. John’s Wort. Am J Med 112: 507–508

    Google Scholar 

  41. Brown TM (2000) Acute St. John’s Wort toxicity. Am J Emerg Med 18: 231–232

    PubMed  Google Scholar 

  42. Ferko N, Levine MA (2001) Evaluation of the association between St. John’s Wort and elevated thyroid-stimulating hormone. Pharmacotherapy 21: 1574–1578

    PubMed  Google Scholar 

  43. Hauben M (2002) The association of St. John’s Wort with elevated thyroid-stimulating hormone. Pharmacotherapy 22: 673–675

    PubMed  Google Scholar 

  44. Siepmann M, Krause S, Joraschky P, Muck-Weymann M, Kirch W (2002) The effects of St John’s Wort extract on heart rate variability, cognitive function and quantitative EEG: a comparison with amitriptyline and placebo in healthy men. Br J Clin Pharmacol 54: 277–282

    PubMed  Google Scholar 

  45. Czekalla J, Gastpar M, Hubner WD, Jager D (1997) The effect of Hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. Pharmacopsychiatry 30(Suppl 2): 86–88

    PubMed  Google Scholar 

  46. Ernst E (2000) Possible interactions between synthetic and herbal medicinal products. Part 1: a systematic review of the indirect evidence. Perfusion 13: 4–15

    Google Scholar 

  47. Ernst E (2000) Interactions between synthetic and herbal medicinal products. Part 2: a systematic review of the direct evidence. Perfusion 13: 60–70

    Google Scholar 

  48. Fugh-Berman A (2000) Herb drug interactions. Lancet 355: 134–138

    PubMed  Google Scholar 

  49. Johne A, Schmider J, Maurer A, Brockmöller J, Mai I, Donath F, Roots I (2000) Arzneimittel-Interaktionen mit Johanniskraut. In: N Rietbrock (ed.): Phytopharmaka in Forschung und klinischer Anwendung VI. Steinkopff-Verlag, Darmstadt, 55–66

    Google Scholar 

  50. Henderson L, Yoe QY, Bergquist C, Gerden B, Arlett P (2002) St John’s Wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54: 349–356

    PubMed  Google Scholar 

  51. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G (2000) Acute heart transplant rejection due to Saint John’s Wort. Lancet 355: 548–549

    PubMed  Google Scholar 

  52. Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Klempnauer J (2000) Drug interaction of St. John’s Wort with cyclosporin. Lancet 355: 1912

    Google Scholar 

  53. Karliova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE (2000) Interaction of Hypericum perforatum (St. John’s Wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 33: 853–855

    PubMed  Google Scholar 

  54. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR (2000) Drug interaction between St. John’s Wort and cyclosporine. Ann Pharmacother 34: 1013–1016

    PubMed  Google Scholar 

  55. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB (2003) Coordinate induction of both cytochrome P4503A and MDR1 by St John’s Wort in healthy subjects. Clin Pharmacol Ther 73: 41–50

    PubMed  Google Scholar 

  56. Bauer S, Stormer E, Johne A, Kruger H, Budde K, Neumayer HH, Roots I, Mai I (2003) Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John’s Wort in renal transplant patients. Br J Clin Pharmacol 55: 203–211

    PubMed  Google Scholar 

  57. Barnes J, Anderson LA, Phillipson JD (2001) St John’s Wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 53: 583–600

    Article  PubMed  Google Scholar 

  58. Bolley R, Zulke C, Kammerl M, Fischereder M, Kramer BK (2002) Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John’s Wort. Transplantation 73: 1009

    Google Scholar 

  59. Mai I, Störmer E, Bauer S, Krüger H, Budde K, Roots I (2003) Impact of St John’s Wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 18: 819–822

    PubMed  Google Scholar 

  60. Maurer A, Johne A, Bauer S, Brockmöller J, Donath F, Roots I, Langheinrich M, Hübner WD (1999) Interaction of St. John’s Wort extract with phenprocoumon. Eur J Clin Pharmacol 55: A22

    Google Scholar 

  61. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000) Indinavir concentrations and St John’s Wort. Lancet 355: 547–548

    PubMed  Google Scholar 

  62. de Maat MM, Hoetelmans RM, Math t RA, van Gorp EC, Meenhorst PL, Mulder JW, Beijnen JH (2001) Drug interaction between St John’s Wort and nevirapine. Aids 15: 420–421

    PubMed  Google Scholar 

  63. Anonymus (2001) Vorsicht: “Pillen”-Versager durch Johanniskraut. Arznei-Telegramm 32: 35

    Google Scholar 

  64. Schwarz UI, Büschel B, Kirch W (2001) Failure of oral contraceptives because of St. John’s Wort. Eur J Clin Pharmacol 57: A25

    Google Scholar 

  65. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P (2002) St John’s Wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54: 349–356

    PubMed  Google Scholar 

  66. Käufeler R, Meier B, Brattström A (2000) Johanniskrautextrakt Ze 117 — Klinische Wirksamkeit und Verträglichkeit. In: N Reitbrock, F Donath, D Loew, I Roots, V Schulz (eds): Phytopharmaka VI: Forschung und Klinische Anwendung. Steinkopff, Darmstadt, 84–89

    Google Scholar 

  67. Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J (2003) Interaction of St John’s Wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Cin Pharmacol 56: 683–690

    Google Scholar 

  68. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC (2003) The interaction between St John’s Wort and oral contraceptive. Clin Pharmacol Ther 74: 525–535

    PubMed  Google Scholar 

  69. Rosenberg MJ Waugh MS, Higgins SE (1996) The effect of desogestrel, gestadone, and other factors on spotting and bleeding. Contraception 53: 85–90

    PubMed  Google Scholar 

  70. Weihrauch TR, Gauler TC (1999) Placebo — Efficacy and adverse effects in controlled clinical trials. Arzneim-Forsch/Drug Res 49: 385–393

    Google Scholar 

  71. Pogge RC (1963) The toxic placebo. Part I — Side and toxic effects reported during the administration of placebo medicine. Part II — The case of the partial patient. Medical Times 91: 773–781

    PubMed  Google Scholar 

  72. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St Johns Wort (Hypericum perforatum). Clin Pharmacol Ther 66: 338–345

    PubMed  Google Scholar 

  73. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K (2000) St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68: 598–604

    PubMed  Google Scholar 

  74. Mueller SC, Uehleke B, Woehling H, Petzsch M, Majches-Perszynska J, Hehl EM, Sievers H, Frank B, Riethling AK, Drewelow B (2004) Effect of St. John’s Wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 75: 546–557

    PubMed  Google Scholar 

  75. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A (2002) Effects of St. John’s Wort on irinotecan metabolism. J Natl Cancer Inst 94: 1247–1249

    PubMed  Google Scholar 

  76. Johne A, Schmider J, Brockmöller J, Stadelmann AM, Störmer E, Bauer S, Scholler G, Langheinrich M, Roots I (2002) Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John’s Wort (Hypericum perforatum). J Clin Psychopharmacol 22: 46–54

    PubMed  Google Scholar 

  77. Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W (2000) Lack of effect of St John’s Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 68: 605–612

    PubMed  Google Scholar 

  78. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura A (2001) Different effects of St John’s Wort on the pharma-cokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 70: 518–524

    PubMed  Google Scholar 

  79. Nebel A, Schneider BJ, Baker RK, Kroll DJ (1999) Potential metabolic interaction between St. John’s Wort and theophylline. Ann Pharmacother 33: 502

    PubMed  Google Scholar 

  80. Wilkinson GR. Pharmacokinetics. In: JG Hardman, LE Limbird (eds): Goodman and Gilman’s the pharmacological basis of therapeutics. MacGraw-Hill, New York, 3–29

    Google Scholar 

  81. Rendic S, Di Carlo FJ (1997) Human cytochrome P450 enzyme: a status report summarizing their reactions, substrates, induction, and inhibitors. Drug Metab Rev 29: 413–580

    PubMed  Google Scholar 

  82. Bodo A, Bakos E, Szeri F (2003) The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 141: 133–143

    Google Scholar 

  83. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT (2000) An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 7: 273–282

    PubMed  Google Scholar 

  84. Ameer B, Weintraub RA (1997) Drug interaction with grapefruit juice. Clin Pharmacokin 33: 103–121

    Google Scholar 

  85. Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, Gallicano KD, Choudri S (2001) An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharmac Sci 4: 176–184

    Google Scholar 

  86. Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH, Bryan M, Budzinski JW, Ramputh A, Arnason JT (2003) In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 10: 334–342

    PubMed  Google Scholar 

  87. Koumaravelou K, Adithan C, Shashindran CH, Asad M, Abraham BK (2002) Effect of honey on carbamazepine kinetics in rabbits. Indian J Exp Biol 40: 560–563

    PubMed  Google Scholar 

  88. Koumaravelou K, Adithan C, Shashindran CH, Asad M, Abraham BK (2002) Influence of honey on orally and intravenously administered diltiazem kinetics in rabbits. Indian J Exp Biol 40: 1164–1168

    PubMed  Google Scholar 

  89. Tsunoda SM, Harris RZ, Christians U, Velez RL, Freeman RB, Benet LZ, Warshaw A (2001) Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 70: 462–467

    PubMed  Google Scholar 

  90. Williams L Hill DP, Davis JA, Lowenthal DT (1996) The influence of food on the absorption and metabolism of drugs: an update. Eur J Drug Metab Pharmacokinet 21: 201–211

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oranienburger Chaussee 25, 13465, Berlin, Germany

    Volker Schulz

  2. Institut für Klinische Pharmakologie, Universitätsklinikum Charite, Schumannstraße 20, 10098, Berlin, Germany

    Andreas Johne

Authors
  1. Volker Schulz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Johne
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut für Naturwissenschaftler, Biozentrum Universität Frankfurt, Marie-Curie-Str.9, 60439, Frankfurt, Germany

    Walter E. Müller

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Schulz, V., Johne, A. (2005). Side effects and drug interactions. In: Müller, W.E. (eds) St. John’s Wort and its Active Principles in Depression and Anxiety. Milestones in Drug Therapy MDT. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7338-5_12

Download citation

Publish with us

Policies and ethics

Search

Navigation